经导管主动脉瓣植入转诊患者中主动脉瓣狭窄合并心脏淀粉样变的患病率与结局
AS-淀粉样变患者年龄更大、生活质量更差、左室壁更厚、心电图电压更低、心肌标志物更高,但TAVI术后并发症率和中位随访19个月的死亡率与单纯AS相似,且TAVI显著改善AS-淀粉样变患者结局。
要点
- 重度AS转诊TAVI的老年患者中,骨闪烁显像提示13%合并心脏淀粉样变。
- AS-淀粉样变患者TAVI术后并发症率和死亡率与单纯AS相似。
- TAVI显著改善AS-淀粉样变患者结局,不应因此拒绝TAVI。
核心结论
- AS-淀粉样变在TAVI转诊的老年重度AS患者中常见,临床特征与单纯AS不同。
- TAVI显著改善AS-淀粉样变患者结局,且围术期并发症和死亡率与单纯AS相似,不应拒绝TAVI。
研究设计与样本
- 基线评估包括超声心动图、心电图、血液检测、6分钟步行试验和健康问卷,随访围术期并发症和死亡率。
主要发现
- AS-淀粉样变26例(13%),其中Grade 1 8例、Grade 2 18例。
- AS-淀粉样变患者年龄更大(88±5 vs. 85±5岁,P=0.001),生活质量更低(EQ-5D-5L 50 vs. 65,P=0.04)。
- 左室壁厚度更高(14 mm vs. 13 mm,P=0.02),心电图电压更低(Sokolow-Lyon 1.9±0.7 vs. 2.5±0.9 mV,P=0.03),电压/质量比更低(0.017 vs. 0.025 mV/g/m2,P=0.03)。
- 高敏肌钙蛋白T和N末端脑钠肽前体更高(41 vs. 21 ng/L,P<0.001;3702 vs. 1254 ng/L,P=0.001)。
- 性别、合并症、6分钟步行距离、AS严重程度、不成比例肥厚患病率及TAVI术后并发症率(38% vs. 35%,P=0.82)无差异;中位随访19(10-27)个月死亡率无差异(P=0.71)。
临床怎么用
- 对≥75岁重度AS拟行TAVI的患者,应考虑筛查心脏淀粉样变。
- 合并AS-淀粉样变不应作为拒绝TAVI的理由。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cardiac amyloidosis is common in elderly patients with aortic stenosis (AS) referred for transcatheter aortic valve implantation (TAVI). We hypothesized that patients with dual aortic stenosis and cardiac amyloid pathology (AS-amyloid) would have different baseline characteristics, periprocedural and mortality outcomes. METHODS AND RESULTS: Patients aged ≥75 with severe AS referred for TAVI at two sites underwent blinded bone scintigraphy prior to intervention (Perugini Grade 0 negative, 1-3 increasingly positive). Baseline assessment included echocardiography, electrocardiogram (ECG), blood tests, 6-min walk test, and health questionnaire, with periprocedural complications and mortality follow-up. Two hundred patients were recruited (aged 85 ± 5 years, 50% male). AS-amyloid was found in 26 (13%): 8 Grade 1, 18 Grade 2. AS-amyloid patients were older (88 ± 5 vs. 85 ± 5 years, P = 0.001), with reduced quality of life (EQ-5D-5L 50 vs. 65, P = 0.04). Left ventricular wall thickness was higher (14 mm vs. 13 mm, P = 0.02), ECG voltages lower (Sokolow-Lyon 1.9 ± 0.7 vs. 2.5 ± 0.9 mV, P = 0.03) with lower voltage/mass ratio (0.017 vs. 0.025 mV/g/m2, P = 0.03). High-sensitivity troponin T and N-terminal pro-brain natriuretic peptide were higher (41 vs. 21 ng/L, P < 0.001; 3702 vs. 1254 ng/L, P = 0.001). Gender, comorbidities, 6-min walk distance, AS severity, prevalence of disproportionate hypertrophy, and post-TAVI complication rates (38% vs. 35%, P = 0.82) were the same. At a median follow-up of 19 (10-27) months, there was no mortality difference (P = 0.71). Transcatheter aortic valve implantation significantly improved outcome in the overall population (P < 0.001) and in those with AS-amyloid (P = 0.03). CONCLUSIONS: AS-amyloid is common and differs from lone AS. Transcatheter aortic valve implantation significantly improved outcome in AS-amyloid, while periprocedural complications and mortality were similar to lone AS, suggesting that TAVI should not be denied to patients with AS-amyloid.
引用
- Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020. PMID: 32267922. doi:10.1093/eurheartj/ehaa170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。